

CV – Denis GLOTZ

Denis GLOTZ, M.D., Ph.D.

Professional Address:

Hopital Saint-Louis

1 avenue Claude Vellefaux 75475 PARIS Cédex 10

Tél. 33.1.42.49.96.31.

FAX: 33.1.42.49.96.06

E-mail: denis.glotz@sls.aphp.fr

Education

- 1972 Bachelor of science, Paris
- 1980 Master of Sciences,
Université Paris VI, Paris
- 1981 Attestation d'Etudes Approfondies en Immunologie
Institut Pasteur, Paris
- 1984 M.D., Faculté de Médecine Saint-Antoine,
Université Paris VI, Paris
- 1990 Specialist in Nephrology, France
- 1990 Ph.D. thesis in Immunology,
Université Paris VI, Paris
- 1992 Diplome d'Habilitation à Direction de Recherches
Université Paris VI, Paris
- 1994 Professor of Nephrology,
Université Paris VI, Paris

Post-doctoral Training

-Internships and residencies

- 1979-1984 Interne des Hopitaux de Paris
- 1987-1991 Chef de clinique-Assistant des Hopitaux, Department of Nephrology, Hopital Broussais,
Paris
- 1991-1994 Praticien Hospitalo-Universitaire,
Department of Nephrology, Hopital Broussais, Paris -Research fellowship
- 1984-1986 Medical Biology Institute, La Jolla, CA
- 1986-1987 University of California San Diego, CA

Academic Appointment

- 1994-2004 Professor of Nephrology, Université Paris VI, Paris
- 2004-present Professor of Nephrology, Université Paris VII, Paris

Hospital Appointment

1988-2000 Head, Renal Transplant Unit, Service de Néphrologie Hopital Broussais, Paris

2000-2004 Head, Renal Transplant Unit, Service de Néphrologie Hopital Européen Georges Pompidou

2004-present Chief, Departement of Nephrology and Renal Transplantation, Hopital Saint-Louis, Paris

Research Activities

1988-2004 Head, Transplant Immunology group,

Unit U 430, INSERM

2004-present Head, Transplant Immunology group,

Unit U 662, INSERM

Societies

American Society of Nephrology, European Dialysis and transplantation Association, French Society of Immunology, French Society of Nephrology, French Society of Transplantation

Committees Assignments

1998-1994 Councilor, Board of Faculté de Medecine Broussais-Hotel Dieu

1993-present Member, regulatory Committee for stable blood-derived products, Agence du Médicament, France

1994-present Member, National Pharmacovigilance Committee, Agence du Médicament, France

1995-present Councilor, French Society of Transplantation

2010: President-elect, French-speaking Society of Transplantation

H INDEX 28

BIBLIOGRAPHY – DENIS GLOTZ

1. Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J, et al. Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. *BJU Int.* 2011 Aug. 2;
2. Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Mercadal L, et al. [Cinacalcet impact on calcium homeostasis and bone remodeling in 13 renal transplanted patients with hyperparathyroidism and hypercalcaemia.]. *Nephrol Ther.* 2011 Jun. 22;
3. Lefaucheur C, Antoine C, Suberbielle C, Glotz D. Mastering the Risk of HLA Antibodies in Kidney Transplantation: An Algorithm Based on Pretransplant Single-Antigen Flow Bead Techniques. *Am J Transplant.* 2011 Jun. 10;
4. Abboud I, Antoine C, Gaudez F, Fieux F, Lefaucheur C, Pillebout E, et al. Pulsatile perfusion preservation for expanded-criteria donors kidneys: Impact on delayed graft function rate. *Int J Artif Organs.* 2011 Jun.;34(6):513–518.
5. Bradley JA, Baldwin WM, Bingaman A, Ellenrieder C, Gebel HM, Glotz D, et al. Antibody-Mediated Rejection-An Ounce of Prevention Is Worth a Pound of Cure. *Am J Transplant.* 2011 Jun.;11(6):1131–1139.
6. Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the endothelial cell within the setting of organ transplantation. *Immunol Lett.* 2011 May 27;
7. Ronda C, Borba SCP, Ferreira SCP, Glotz D, Ianhez LE, Rodrigues H, et al. Non-human leukocyte antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts. *Transplant Proc.* 2011 May;43(4):1345–1348.
8. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. *Journal of the American Society of Nephrology.* 2011 Apr. 14;
9. Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. *Nephrol Dial Transplant.* 2011 Mar. 24;:1–3.
10. Canet E, Osman D, Lambert J, Guitton C, Heng A-E, Argaud L, et al. Acute respiratory failure in kidney transplant recipients: a multicenter study. *Crit Care.* 2011 Mar. 8;15(2):R91.
11. Venot M, Abboud I, Duboust A, Michel C, Suberbielle C, Verine J, et al. Calcineurin inhibitor-free monotherapy in human leukocyte antigen-identical live donor renal transplantation. *Transplantation.* 2011 Feb. 15;91(3):330–333.
12. Taflin C, Favier B, Baudhuin J, Savenay A, Hemon P, Bensussan A, et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. *Proc Natl Acad Sci USA.* 2011 Feb. 15;108(7):2891–2896.
13. Viglietti D, Verine J, de Castro N, Scemla A, Daudon M, Glotz D, et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. *Antivir. Ther. (Lond.).* 2011;16(1):119–121.
14. Hantz S, Garnier-Geoffroy F, Mazeron M-C, Garrigue I, Merville P, Mengelle C, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. *J. Antimicrob. Chemother.* 2010 Dec.;65(12):2628–2640.
15. Dantal J, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. *Transpl Int.* 2010 Nov.;23(11):1084–1093.
16. Bollée G, Martinez F, Moulin B, Meulders Q, Rougier J-P, Baumelou A, et al. Renal biopsy practice in France: results of a nationwide study. *Nephrol Dial Transplant.* 2010 Nov.;25(11):3579–3585.

17. Touzot M, Pillebout E, Matignon M, Tricot L, Viard JP, Rondeau E, et al. Renal transplantation in HIV-infected patients: the Paris experience. *Am J Transplant*. 2010 Oct.;10(10):2263–2269.
18. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. *Journal of the American Society of Nephrology*. 2010 Aug.;21(8):1398–1406.
19. Champion L, Durrbach A, Lang P, Delahousse M, Chauvet C, Sarfati C, et al. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. *Am J Transplant*. 2010 Aug.;10(8):1925–1930.
20. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rife G, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. *Transplantation*. 2010 Jun. 27;89(12):1511–1517.
21. Abboud I, Galicier L, de Labarthe A, Dossier A, Glotz D, Verine J. A paraneoplastic membranoproliferative glomerulonephritis with isolated C3 deposits associated with hairy cell leukaemia. *Nephrol Dial Transplant*. 2010 Jun.;25(6):2026–2028.
22. Touzot M, Touzot F, Galicier L, Ripault M-P, Peraldi MN, Glotz D, et al. Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. *Clin Nephrol*. 2010 Apr.;73(4):318–320.
23. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. 2010 Apr.;52(4):605–613.
24. Glotz D. Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids. *Transplantation*. 2010 Mar. 17;:1–9.
25. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. *Am J Transplant*. 2010 Mar.;10(3):464–471.
26. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. *Arthritis Rheum*. 2010 Feb.;62(2):616–626.
27. Taflin C, Nochy D, Hill G, Frouget T, Rioux N, Verine J, et al. Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. *Transplantation*. 2010 Jan. 27;89(2):194–199.
28. International Summit on Transplant Tourism and Organ Trafficking. The declaration of Istanbul on organ trafficking and transplant tourism. *Saudi J Kidney Dis Transpl*. 2010 Jan.;21(1):138–147.
29. Jordan SC, Glotz D. Is rituximab safe to use in kidney transplant patients? *Am J Transplant*. 2010 Jan.;10(1):8–9.
30. Ploussard G, Mongiat-Artus P, Meria P, Tariel E, Gaudez F, de Kerviler E, et al. What is the relevance of systematic aorto-femoral Doppler ultrasound in the preoperative assessment of patients awaiting first kidney transplantation: a monocentric prospective study. *Nephrol Dial Transplant*. 2010 Jan.;25(1):270–274.
31. Frimat L, Cassuto-Viguiet E, Provôt F, Rostaing L, Charpentier B, Akposso K, et al. Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up. *J Transplant*. 2010;2010.
32. Servais A, Meas-Yedid V, Toupance O, Lebranchu Y, Thierry A, Moulin B, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. *Am J Transplant*. 2009 Nov.;9(11):2552–2560.
33. Abboud I, Porcher R, Robin M, de Latour RP, Glotz D, Socié G, et al. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. *Biol. Blood Marrow Transplant*. 2009 Oct.;15(10):1251–1257.
34. Albano L, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, et al. Incidence of delayed graft

function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. *Transplantation*. 2009 Jul. 15;88(1):69–76.

35. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. *Am J Transplant*. 2009 May;9(5):1099–1107.
36. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al. Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study. *American Journal of Transplantation*. 2009 May;9(5):1115–1123.
37. Peraldi M-N, Berrou J, Dulphy N, Seidowsky A, Haas P, Boissel N, et al. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients. *J Immunol*. 2009 Feb. 1;182(3):1696–1705.
38. Billaud EM, Antoine C, Berge M, Abboud I, Lefeuvre S, Benammar M, et al. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. *Clin Drug Investig*. 2009;29(7):481–486.
39. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. *Contributions to nephrology*. 2009;162:1–12.
40. Choukroun G, Deray G, Glotz D, Lebranchu Y, Dussol B, Bourbigot B, et al. [Incidence and management of anemia in renal transplantation: an observational-French study]. *Nephrol Ther*. 2008 Dec.;4(7):575–583.
41. Chambade D, Meria P, Tariel E, Verine J, de Kerviler E, Peraldi MN, et al. Nephron sparing surgery is a feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from a single center. *J. Urol*. 2008 Nov.;180(5):2106–2109.
42. Anglicheau D, Loupy A, Lefaucheur C, Pessione F, Létourneau I, Côté I, et al. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. *Am J Transplant*. 2008 Nov.;8(11):2325–2334.
43. Tobian AAR, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. *Transfusion*. 2008 Nov.;48(11):2453–2460.
44. Lefaucheur C, Nochy D, Glotz D. [Antibody-mediated acute rejection]. *Néphrologie thérapeutique*. 2008 Oct.;4 Suppl 3(S3):S188–91.
45. Lefaucheur C, Nochy D, Amrein C, Chevalier P, Guillemain R, Cherif M, et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. *Am J Transplant*. 2008 Sep.;8(9):1901–1910.
46. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel P-Y, et al. Early epithelial phenotypic changes predict graft fibrosis. *Journal of the American Society of Nephrology*. 2008 Aug.;19(8):1584–1591.
47. Glotz D. [Post-transplantation anti-HLA antibodies: which relevance?]. *Nephrol Ther*. 2008 Jun. 1;4 Suppl 1:S8–S12.
48. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant*. 2008 Apr.;8(4):753–760.
49. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. *Am J Transplant*. 2008 Feb.;8(2):324–331.
50. Mazoyer E, Daugas E, Verine J, Pillebout E, Mourad N, Molina J-M, et al. A case report of adenovirus-related acute interstitial nephritis in a patient with AIDS. *Am J Kidney Dis*. 2008 Jan.;51(1):121–126.
51. Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, Antoine C, Charron D, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. *Am J Transplant*. 2007 Apr.;7(4):832–841.

52. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. *Am J Transplant.* 2006 Dec.;6(12):2937–2946.
53. Mai H, Champion L, Ouali N, Hertig A, Peraldi M-N, Glotz D, et al. *Candida albicans* arteritis transmitted by conservative liquid after renal transplantation: a report of four cases and review of the literature. *Transplantation.* 2006 Nov. 15;82(9):1163–1167.
54. Frimat L, Cassuto-Viguiet E, Charpentier B, Noël C, Provôt F, Rostaing L, et al. Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The “Reference” Study. *Am J Transplant.* 2006 Nov.;6(11):2725–2734.
55. Boulanger H, Mansouri R, Gautier JF, Glotz D. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? *Nephrol Dial Transplant.* 2006 Oct.;21(10):2696–2702.
56. Lefaucheur C, Hill GS, Amrein C, Haymann J-P, Jacquot C, Glotz D, et al. Acute oxalate nephropathy: A new etiology for acute renal failure following nonrenal solid organ transplantation. *Am J Transplant.* 2006 Oct.;6(10):2516–2521.
57. Glotz D, Lucchiari N, Pegaz-Fiorinet B, Suberbielle-Boissel C. Endothelial cells as targets of allograft rejection. *Transplantation.* 2006 Jul. 15;82(1 Suppl):S19–21.
58. Si-Mohamed A, Goff JL, Désiré N, Maylin S, Glotz D, Bélec L. Detection and quantitation of BK virus DNA by real-time polymerase chain reaction in the LT-ag gene in adult renal transplant recipients. *J. Virol. Methods.* 2006 Jan.;131(1):21–27.
59. Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Sarfati E, et al. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. *Nephrol Dial Transplant.* 2005 Dec.;20(12):2865.
60. Chalem Y, Ryckelynck J-P, Tuppin P, Verger C, Chauvé S, Glotz D, et al. Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. *Kidney Int.* 2005 Jun.;67(6):2448–2453.
61. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). *Am J Transplant.* 2005 May;5(5):1120–1129.
62. Glotz D, Antoine C, Duboust A. Antidonor antibodies and transplantation: how to deal with them before and after transplantation. *Transplantation.* 2005 Feb. 15;79(3 Suppl):S30–2.
63. Godard B, Gazagne A, Gey A, Baptiste M, Vingert B, Pegaz-Fiorinet B, et al. Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. *Hum Immunol.* 2004 Nov.;65(11):1307–1318.
64. Duong Van Huyen J-P, Fornes P, Guillemain R, Amrein C, Chevalier P, Latremouille C, et al. Acute vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d immunofluorescence. *Hum Pathol.* 2004 Mar.;35(3):385–388.
65. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. *Transplantation.* 2004 Feb. 27;77(4):542–548.
66. Glotz D, Antoine C, Julia P, Pegaz-Fiorinet B, Duboust A, Boudjeltia S, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. *Transpl Int.* 2004 Jan.;17(1):1–8.
67. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. *Am J Transplant.* 2003 Jun.;3(6):708–714.
68. Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine J-L, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. *Transplantation.* 2003 Mar.;75(6):844–851.
69. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). *Am J Transplant.*

2002 Sep.;2(8):758–760.

70. Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Rémy P, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. *Kidney Int.* 2002 Jun.;61(6):2176–2186.
71. Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. *J Am Soc Nephrol.* 2001 Dec. 1;12(12):2807–2814.
72. de Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. *Am. J. Med.* 2001 Oct. 1;111(5):417–418.
73. Mourad G, Garrigue V, Squifflet JP, Besse T, Berthoux F, Alamartine E, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. *Transplantation.* 2001 Sep. 27;72(6):1050–1055.
74. Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. *Kidney Int.* 2001 Jul. 1;60(1):341–349.
75. Antoine C, Hill G, Glotz D, Fontanière B, Tabone E, Nochy D. [Polyomavirus and tubulointerstitial nephropathy]. *Néphrologie.* 2001;22(6):317–320.
76. Braunberger E, Cohen JL, Boyer O, Pegaz-Fiornet B, Raynal-Raschilas N, Bruneval P, et al. T-Cell suicide gene therapy for organ transplantation: induction of long-lasting tolerance to allogeneic heart without generalized immunosuppression. *Mol Ther.* 2000 Dec. 1;2(6):596–601.
77. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. *Transplantation.* 2000 Sep. 27;70(6):887–895.
78. Thomas-Vaslin V, Bellier B, Cohen JL, Boyer O, Raynal-Raschilas N, Glotz D, et al. Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. *Transplantation.* 2000 May 27;69(10):2154–2161.
79. Lucchiari N, Panajotopoulos N, Xu C, Rodrigues H, Ianhez LE, Kalil J, et al. Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. *Hum Immunol.* 2000 May;61(5):518–527.
80. Lebranchu Y, Aubert P, Bayle F, Bedrossian J, Berthoux F, Bourbigot B, et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group. *Transplant Proc.* 2000 Mar. 1;32(2):396–397.
81. Thervet E, Charpentier B, Durand D, Glotz D, Lebranchu Y, Lefrançois N, et al. Early renal function deterioration is the only predictive factor of graft failure after 1 year. *Transplant Proc.* 2000 Mar. 1;32(2):425–426.
82. Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. *Transplant Proc.* 2000 Mar.;32(2):384–385.
83. Ball B, Mousson C, Ratignier C, Guignier F, Glotz D, Rife G. Antibodies to vascular endothelial cells in chronic rejection of renal allografts. *Transplant Proc.* 2000 Mar.;32(2):353–354.
84. Rérolle J-P, Antoine C, Raynaud A, Beyssen B, Julia P, Duboust A, et al. Successful endoluminal thromboaspiration of renal graft venous thrombosis. *Transplant Proc.* 2000 Mar.;32(2):399–400.
85. Lahlou A, Lang P, Charpentier B, Barrou B, Glotz D, Baron C, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Île-de-France (GCIF). *Medicine (Baltimore).* 2000 Mar.;79(2):90–102.
86. Braunberger E, Raynal-Raschilas N, Thomas-Vaslin V, Bruneval P, Fabiani JN, Carpentier A, et al. Tolerance induced without immunosuppression in a T-lymphocyte suicide-gene therapy cardiac allograft

model in mice. *J Thorac Cardiovasc Surg.* 2000 Jan.;119(1):46–51.

87. R  rolle J-P, Antoine C, Raynaud A, Beyssen B, Julia P, Duboust A, et al. Successful endoluminal thrombo-aspiration of renal graft venous thrombosis. *Transpl Int.* 2000;13(1):82–86.
88. Nochy D, Antoine C, Fontani  re B, Tabone E, Mainardi JL, Glotz D. [Urinary cytology during kidney transplantation]. *Ann Pathol.* 2000;20 Suppl:S79–81.
89. Glotz D, Antoine C, Haymann J-P, Julia P, Duboust A, Bari  ty J. Intravenous immunoglobulins and kidney transplantation in patients with anti-HLA antibodies. *Adv Nephrol Necker Hosp.* 2000;30:221–233.
90. Mahoney RJ, Breggia AE. Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')₂ dimers, monomers, and monovalent F(ab). *Hum Immunol.* 1999 Jun. 1;60(6):492–499.
91. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int.* 1999 Feb.;55(2):713–723.
92. Glotz D. [Xenotransplantation: from the myth to the possible]. *N  phrologie.* 1999;20(4):187–188.
93. Antoine C, Thakur S, Daugas E, Fraoui R, Boudjeltia S, Julia P, et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. *TPS.* 1998 Sep. 1;30(6):2813–2814.
94. Shah B, Antoine C, Mercier F, Julia P, Duboust A, Glotz D. Successful kidney retransplantation after combined liver/kidney transplantation in primary hyperoxaluria type I. *Nephrol Dial Transplant.* 1998 Jun.;13(6):1568–1570.
95. Bari  ty J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. *Kidney Int.* 1998 Apr. 1;53(4):918–925.
96. Schussler O, Genevaz D, Latremouille C, Goussev N, Kaveri S, Glotz D. Intravenous immunoglobulins for therapeutic use contain anti-idiotypes against xenophile antibodies and prolong discordant graft survival. *Clin. Immunol. Immunopathol.* 1998 Feb.;86(2):183–191.
97. Latremouille C, Genevaz D, Hu MC, Schussler O, Goussef N, Mandet C, et al. Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')₂-mediated anti-complement activity. *Clin Exp Immunol.* 1997 Oct.;110(1):122–126.
98. Gauffre A, Mircheva J, Glotz D, Fillastre JP, Simon P, Beaune PH, et al. Autoantibodies against a kidney--liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis. *Nephrol Dial Transplant.* 1997 Sep.;12(9):1961–1962.
99. Schussler O, Latremouille C, Genevaz D, Carpentier A, Glotz D. Normal human polyclonal immunoglobulins for intravenous use contain anti-idiotypes against natural xenophile antibodies and prolong discordant xenograft survival. *Transplant Proc.* 1997 Jan.;29(1-2):959–960.
100. Schussler O, Lantoine F, Devynck MA, Glotz D, David-Duflho M. Human immunoglobulins inhibit thrombin-induced Ca²⁺ movements and nitric oxide production in endothelial cells. *J Biol Chem.* 1996 Oct. 25;271(43):26473–26476.
101. Antoine C, Garnier JL, Duboust A, Bari  ty J, Stevenson G, Glotz D. Successful treatment of posttransplant lymphoproliferative disorder with renal graft preservation by monoclonal antibody therapy. *Transplant Proc.* 1996 Oct.;28(5):2825–2826.
102. Genevaz D, Latremouille C, Goussev N, Carpentier A, Glotz D. Normal human polyclonal immunoglobulins delay xenograft rejection through distinct F(ab')₂ and Fc mediated mechanisms. *Transplant Proc.* 1996 Apr.;28(2):853–854.
103. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. *J Clin Invest.* 1996 Feb. 1;97(3):865–869.
104. Vincent F, Michel M, Marrast AC, Bensousan TA, Glotz D, Duboust A. Management of ovarian cancer in the renal transplant recipient with cyclophosphamide used as an immunosuppressive and antineoplastic agent. *Transplant Proc.* 1995 Aug.;27(4):2432.

105. Calonge VM, Glotz D, Bouscary D, Duboust A, Bruneval P, Druet P, et al. Hemophagocytic histiocytosis (HH) in renal transplant recipients under ciclosporin therapy: report of the first two cases. *Clin Transplant*. 1995 Apr.;9(2):88–91.
106. Vincent F, Raynal N, Duboust A, Glotz D, Bariéty J. Influence of epinephrine treatment of the organ donor on acute tubular necrosis following renal transplantation. *Transplant Proc*. 1995 Apr.;27(2):1649.
107. Vincent F, Raynal N, Francois A, Belec L, Duboust A, Glotz D, et al. False-positive p24 antigenaemia detected in renal allograft recipients: possible role of rabbit antithymocyte globulins. *Transplant Proc*. 1995 Apr.;27(2):1738.
108. Garnier JL, Berger F, Martin X, Dureau G, Mornex JF, Glotz D, et al. Post-transplant B-cell lymphomas--correlation of late stage B-cell differentiation and progression of disease; treatment with chimeric monoclonal antibody. *Transplant Proc*. 1995 Apr.;27(2):1777.
109. Vincent F, Duboust A, Glotz D. Pneumatosis cystoides intestinalis and immunosuppression. *Am. J. Gastroenterol*. 1995 Mar.;90(3):522–523.
110. Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc'h A, Glotz D. Invasive aspergillosis after transplantation. *Transplant Proc*. 1995 Feb.;27(1):1307–1309.
111. Glotz D, Haymann J-P, Niaudet P, Lang P, Druet P, Bariéty J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. *Transplant Proc*. 1995 Feb.;27(1):1038–1039.
112. Vincent F, Levy V, Bensousan TA, Glotz D, Duboust A, Escudier B, et al. "Spontaneous" regressions of a metastatic adenocarcinoma transmitted by a cadaver kidney graft: support for immunotherapy? *Cancer Immunol. Immunother*. 1994 Sep.;39(3):205–206.
113. Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc'h A, Glotz D. [Aspergillosis and renal, heart and lung transplantation]. *Pathol. Biol*. 1994 Sep.;42(7):661–669.
114. Nochy D, Heudes D, Glotz D, Lemoine R, Gentric D, Bruneval P, et al. Preeclampsia associated focal and segmental glomerulosclerosis and glomerular hypertrophy: a morphometric analysis. *Clin Nephrol*. 1994 Jul.;42(1):9–17.
115. Sundblad A, Marcos MA, Malanchere E, Castro A, Haury M, Huetz F, et al. Observations on the mode of action of normal immunoglobulin at high doses. *Immunol Rev*. 1994 Jun. 1;139:125–158.
116. Nochy D, Glotz D, Goucha R, Pelletier L, Bariéty J. [Renal involvements in human immunodeficiency virus infection]. *La Revue du praticien*. 1994 Jun. 1;44(11):1494–1499.
117. Latremouille C, Haeffner-Cavaillon N, Goussef N, Mandet C, Hinglais N, Bruneval P, et al. Normal human polyclonal immunoglobulins for intravenous use significantly delay hyperacute xenograft rejection. *Transplant Proc*. 1994 Jun.;26(3):1285.
118. Vincent F, Glotz D, Kreft-Jais C, Boudjeltia S, Duboust A, Bariéty J. [Acute kidney failure in a patient treated with cyclosporine A and metronidazole following kidney transplantation]. *Therapie*. 1994 Feb.;49(2):155.
119. Plainfossé MC, Grataloup C, Glotz D, Sareeh A, Beyloune-Mainardi C, Duboust A, et al. [The transplanted kidney. Role of imaging in early non-functioning grafts]. *J Radiol*. 1994 Jan.;75(1):25–30.
120. Glotz D, Haymann J-P, Sansonetti N, Francois A, Menoyo-Calonge V, Bariéty J, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. *Transplantation*. 1993 Aug.;56(2):335–337.
121. Vincent F, Belec L, Glotz D, Menoyo-Calonge V, Duboust A, Bariéty J. False-positive neutralizable HIV antigens detected in organ transplant recipients. *AIDS*. 1993 May;7(5):741–742.
122. Nochy D, Glotz D, Dosquet P, Pruna A, Lemoine R, Guettier C, et al. Renal lesions associated with human immunodeficiency virus infection: North American vs. European experience. *Adv Nephrol Necker Hosp*. 1993;22:269–286.
123. Nochy D, Glotz D, Dosquet P, Pruna A, Guettier C, Weiss L, et al. Renal disease associated with HIV

- infection: a multicentric study of 60 patients from Paris hospitals. *Nephrol Dial Transplant*. 1993;8(1):11–19.
124. Glotz D, Kazatchkine M, Vincent F, Haddad H, Duboust A, Druet P, et al. [Pneumocystis carinii pneumonia in a kidney transplantation center in the proximity of an AIDS care unit]. *Presse Med*. 1992 Nov.;21(44):2154.
 125. Plainfossé MC, Calonge VM, Beyloune-Mainardi C, Glotz D, Duboust A. Vascular complications in the adult kidney transplant recipient. *J Clin Ultrasound*. 1992 Oct.;20(8):517–527.
 126. Glotz D, Druet P. [role of cellular immunity in the genesis of rapidly progressive glomerulonephritis]. *Néphrologie*. 1992;13(6):255–257.
 127. Glotz D, Bariéty J, Druet P. [Extramembranous glomerulopathies]. *La Revue du praticien*. 1991 Nov. 15;41(24):2424–2429.
 128. Glotz D. [Anti-idiotypic antibodies]. *La Revue du praticien*. 1991 Mar. 21;41(9):801–806.
 129. Glotz D, Jouvin MH, Nochy D, Druet P, Bariéty J. Recurrent acute glomerulonephritis. *Am J Kidney Dis*. 1991 Feb. 1;17(2):228–230.
 130. Misset B, Glotz D, Escudier B, Nochy D, Bosq J, Gilles E, et al. Wegener's granulomatosis presenting as diffuse pulmonary hemorrhage. *Intensive care medicine*. 1991 Jan. 1;17(2):118–120.
 131. Jebara VA, Fabiani JN, Moulouguet-Deloris L, Acar C, Debauchez M, Chachques JC, et al. Abdominal aortic aneurysmectomy in renal transplant patients. *Texas Heart Institute journal / from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital*. 1990 Jan. 1;17(3):240–244.
 132. Guéry JC, Druet E, Glotz D, Hirsch F, Mandet C, de Heer E, et al. Specificity and cross-reactive idiotypes of anti-glomerular basement membrane autoantibodies in HgCl₂-induced autoimmune glomerulonephritis. *Eur J Immunol*. 1990 Jan.;20(1):93–100.
 133. Sollazzo M, Hasemann CA, Meek KD, Glotz D, Capra JD, Zanetti M. Molecular characterization of the VH region of murine autoantibodies from neonatal and adult BALB/c mice. *Eur J Immunol*. 1989 Mar. 1;19(3):453–457.
 134. Glotz D, Zanetti M. A natural neonatal hybridoma autoantibody to the T200 antigen. *J Immunol*. 1989 Jan. 15;142(2):439–443.
 135. Molinaro GA, Glotz D, Zanetti M. Early ontogeny of rheumatoid factor antibodies. Characterization of a murine neonatal hybridoma autoantibody to IgG1 in BALB/c mice. *Autoimmunity*. 1989 Jan. 1;4(1-2):9–19.
 136. Sollazzo M, Glotz D, Castiglia D, Zanetti M. Autoantibody idiotype and neonatal B cell repertoire. *Viral Immunol*. 1989 Jan. 1;2(4):263–269.
 137. Glotz D, Sollazzo M, Riley S, Zanetti M. Isotype, VH genes, and antigen-binding analysis of hybridomas from newborn normal BALB/c mice. *J Immunol*. 1988 Jul. 15;141(2):383–390.
 138. Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. *Proc Natl Acad Sci USA*. 1988 Apr. 1;85(8):2753–2757.
 139. Zanetti M, Glotz D. Considerations on thymus-dependent and -independent antigens in acquired and natural immunity. *Ann Inst Pasteur Immunol*. 1988 Jan. 1;139(2):192–193.
 140. Zanetti M, Glotz D, Sollazzo M. Idiotype regulation of self responses, autoantibody V regions and neonatal B cell repertoire. *Immunol Lett*. 1987 Dec. 1;16(3-4):277–282.
 141. Guéry JC, Druet E, Glotz D, Hirsch F, Kuhn J, Lymbery P, et al. Idiotypes of autoantibodies in mercury-induced autoimmunity in the rat. *Monogr Allergy*. 1987;22:99–108.